問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

羅竹君

Recruiting

List

62Cases

2025-07-01 - 2035-12-31

Phase III

Not yet recruiting
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04)

  • Condition/Disease

    Breast Neoplasms

  • Test Drug

    注射劑 錠劑 注射劑 注射劑

Participate Sites
7Sites

Recruiting7Sites

2018-10-01 - 2031-09-01

Phase III

Active
A Randomized, Double-Blind, Phase III Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy for the Treatment of High-Risk Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (KEYNOTE-756)

  • Condition/Disease

    ER+/HER2- Breast Cancer

  • Test Drug

    Keytruda

Participate Sites
5Sites

Recruiting2Sites

Terminated3Sites

2025-02-01 - 2033-12-31

Phase II

Completed
A Phase 2, Umbrella Study to Evaluate the Safety, Tolerability, and Clinical Activity of Investigational Agents for Newly Diagnosed, High-Risk, Early-Stage Triple-Negative Breast Cancer

  • Condition/Disease

    Early Triple Negative Breast Cancer

  • Test Drug

    注射劑 注射劑

Participate Sites
3Sites

Recruiting3Sites

2017-03-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-04-01 - 2035-12-31

Phase II

Not yet recruiting
An Open-label Randomized Phase 2 Study to Evaluate Safety and Efficacy of Patritumab Deruxtecan Plus Pembrolizumab Administered Either Before or After Carboplatin/Paclitaxel Plus Pembrolizumab Compared With Pembrolizumab in Combination With Chemotherapy Followed by Surgery and Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer (HERTHENA-Breast03)

  • Condition/Disease

    Breast Neoplasms 、Breast Cancer

  • Test Drug

    注射劑 注射劑

Participate Sites
3Sites

Recruiting3Sites

2023-10-02 - 2026-12-31

Phase III

Completed
A Multicenter, Double-blind, Randomized, Parallel-group, Phase 3 Study to Compare the Efficacy and Safety of the Proposed Biosimilar PERT-IJS and EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Patients With Hormone Receptor Negative (HR-ve) Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Early Stage or Locally Advanced Breast Cancer

  • Condition/Disease

    HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

  • Test Drug

    PERT-IJS (Bmab 1500)

Participate Sites
7Sites

Recruiting7Sites

2025-02-28 - 2032-06-30

Phase III

Active
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast Cancer with High Risk of Recurrence - A Global, Multicenter, Randomized, Open-label Phase 3 Study (ELEGANT)

  • Condition/Disease

    Early breast cancer that is lymph node–positive, estrogen receptor–positive, and human epidermal growth factor receptor 2 (HER2)–negative, with a high risk of recurrence.

  • Test Drug

    Elacestrant

Participate Sites
13Sites

Recruiting13Sites

2021-09-01 - 2029-10-31

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2025-06-06 - 2028-09-13

Phase III

Active
VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer

  • Condition/Disease

    Breast Cancer

  • Test Drug

    Infusion fluid

Participate Sites
7Sites

Recruiting7Sites

2021-09-27 - 2028-02-15

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB